

Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Summary of Consolidated Financial Results (For the First Quarter ended June 30, 2023) [Under Japanese GAAP]

August 2, 2023
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.

Code number: 4569

Web site: <https://www.kyorin-pharm.co.jp/>

Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer

Contact: Sakurou Banba, Director, Finance & Accounting

TEL (03) 3525-4701

Scheduled date for submitting securities report: August 9, 2023

Scheduled date for starting dividend payment: -

(Amounts rounded down to the nearest million yen)

1. Consolidated results for the three months ended June 30, 2023 (from April 1, 2023 to June 30, 2023)

(1) Consolidated operating results

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Three months ended June 30, 2023	27,854	13.1	710	45.1	913	17.2	676	-42.8
June 30, 2022	24,619	-0.3	489	—	779	—	1,183	—

(Note) Comprehensive income: For the three months ended June 30, 2023: 1,152 million yen (-51.3%),
For the three months ended June 30, 2022: 2,367 million yen (—%)

	Earnings per share (Basic)	Earnings per share (Diluted)
	Yen	Yen
Three months ended June 30, 2023	11.81	—
June 30, 2022	20.65	—

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
As of June 30, 2023	172,542	124,753	72.3
March 31, 2023	176,045	125,461	71.3

(Note) Equity: For the three months ended June 30, 2023: 124,753 million yen,
For the fiscal year ended March 31, 2023: 125,461 million yen

2. Dividends

(Record date)	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2023	—	20.00	—	32.00	52.00
Fiscal year ended March 31, 2024	—				
Fiscal year ending March 31, 2024 (Forecast)		20.00	—	32.00	52.00

(Note) Revisions to the dividend forecast in the current quarter: None

3. Forecast of consolidated for the year ending March 31, 2024 (from April 1, 2023 to March 31, 2024)

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	53,700	9.4	600	-22.9	900	-23.2	700	-43.7	12.22
Full year	116,200	2.6	6,000	17.1	6,500	11.5	4,900	3.7	85.51

(Note) Revisions to the dividend forecast in the current quarter: None

4. Other

(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): Yes

Newly included: None

Excluded: 1 company (The former Kyorin Pharmaceutical Co. Ltd.)

(2) Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other than (i) : None

(iii) Changes in accounting estimates : Yes

(iv) Restatements : None

(4) Number of shares issued (common stock)

(i) Number of issued shares at the end of the period (including treasury shares)

As of June 30, 2023: 64,607,936 shares,

Fiscal year ended March 31 2023: 64,607,936 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2023: 7,304,078 shares,

Fiscal year ended March 31 2023: 7,304,066 shares

(iii) Averaged number of shares of during the period

As of June 30, 2023: 57,303,858 shares,

As of June 30, 2022: 57,301,882 shares

* This quarterly financial report is not subject to audit procedures by Certified Public Accountants or audit firm.

* Explanations about the appropriate use of the business forecasts and other noteworthy points.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)

Supplementary materials will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.